ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel
نویسندگان
چکیده
منابع مشابه
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Recently, the G1199T/A polymorphism in the ABCB1 gene was shown to be important for the function of P-gp as well as for the resistance to several chemotherapeutic agents in vitro. We analyzed the allelic distribution of the G1199T/A and other polymorphi...
متن کاملPaclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer
ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer. A significant association between common single nucleotide polymorphisms (SNPs) in ABCB1 and progression-free survival has been reported in patients with ovarian cancer. Variable paclitaxel clearance du...
متن کاملDoes MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy?
To the Editor: In the February 1, 2006 issue of Clinical Cancer Research , Gréen et al. (1) described an association between G2677A/T single nucleotide polymorphism of MDR-1 gene and response to paclitaxel chemotherapy. The investigators state that ‘‘the probability of responding to paclitaxel treatment is higher in homozygously mutated patients (TT or TA)’’. In our opinion, there are some issu...
متن کاملMicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
BACKGROUND Recent studies have shown that microRNAs may regulate the ABCB1 gene (ATP-binding cassette, sub-family B [MDR/TAP], member 1). Computational programs have predicted that the 3'-untranslated region (3'-UTR) of ABCB1 contains a potential miRNA-binding site for miR-186. Here, we investigated the role of miR-186 in sensitizing ovarian cancer cells to paclitaxel and cisplatin. RESULTS H...
متن کاملABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
TotheEditor: Gréen et al. (1) identified ABCB1 2677G>T/A genotype as a marker of response to paclitaxel therapy in ovarian cancer. Their study was done in 53 tumor samples from ovarian cancer patients treated with 175 or 135 mg/m paclitaxel for at least four cycles. Response was higher in patients with the variant (T or A) alleles (P < 0.05), and increasing number of variant alleles increased t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical Sciences
سال: 2008
ISSN: 0022-3549
DOI: 10.1002/jps.21169